News Releases

Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023 Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs PHILADELPHIA, March 7, 2023 /PRNewswire/ -- 

Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE Proxy Card Today CAMBRIDGE, Mass.

Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards’ Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio’s

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2023-- Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”) management team on Tuesday, February 21, 2023 , at 8:00 am ET .

Sesen Bio Board Unanimously Recommends All Stockholders to Vote “FOR” the Value Maximizing Merger on the WHITE Proxy Card Today CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 15, 2023-- Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P.

Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027 Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction Michael Torok to Join Carisma Board of Directors as Only Sesen Bio

PHILADELPHIA, Feb. 7, 2023 /PRNewswire/ --  Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the appointment of Lin Guey, PhD to the company's Scientific Advisory Board (SAB). Dr.

Highlights Board’s Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders Urges Stockholders to Vote “FOR” Transaction Ahead of Special Meeting of Stockholders on March 2, 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb.

Expansion of Scientific Advisory Board provides additional expertise in development capabilities PHILADELPHIA, Jan. 31, 2023 /PRNewswire/ --  Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced the

Company Calls Out Misrepresentations from Investor Group CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 26, 2023-- Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc.